Mind Cure Signs LOI To Take Equity Stake In Psychedelic Treatment Centre

Mind Cure Health (CSE: MCUR) has signed a non-binding letter of intent to conduct a strategic investment into that of ATMA Journey Centers Inc. The arrangement, which is to also include a commercial cooperation agreement, will see the company secure an equity position within the firm, which is the first commercial treatment centre in Canada providing psychedelic-assisted therapy for exempt patients.

Based in Calgary, ATMA is focused on section 56 exempt patients, to whom it offers this psychedelic-assisted therapy. The company is the first such provider in Canada, with the exemption enabling the company to provide the assisted therapy to patients whom are seeking such a type of healthcare.

The collaboration between the two parties will also see ATMA researchers and therapists partake in Mind Cure’s research programs into pain, migraines, cluster headaches and neuroregeneration. The arrangement will also see the exclusive use of the firms iSTRYM digital therapeutics platform throughout ATMA’s operations, providing speed and scale for data enrichment of the psychedelics-focused technology platform, while also providing further access to patient data.

“ATMA’s clinicians possess a proven track record of advocacy and innovation driving toward the therapeutic benefits of psychedelic medicine for patients in the treatment of mental health and wellness. With Mind Cure’s therapeutic tool, iSTRYM, along with ATMA’s pivotal achievement as the care provider for Canada’s most recent section 56(1) exempt patient, mental health care in Canada is making history.”

Kelsey Ramsden, President & CEO of Mind Cure

The current non-binding letter of intent signed by the two firms proposes an initial investment of $500,000 by Mind Cure into that of ATMA for an undisclosed stake in the operation. The arrangement will also see the involvement of Mind Cure in future financings conducted by ATMA, as well as the previously mentioned exclusive use of iSTRYM throughout ATMA’s operations. A definitive agreement is expected to be negotiated by the two firms on a go-forward basis.

Mind Cure Health last traded at $0.68 on the CSE.


FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Gold is Up 30%, But the Real Bull Market is Only Starting Now! | Adrian Day

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News

Mindcure Ends Fiscal Q1 2022 With $15.6 Million Cash & Cash Equivalents, $2.8 Million Net Loss

Mind Cure Health (CSE: MCUR) announced on Tuesday the financial results for the three months ended...

Wednesday, October 27, 2021, 10:41:00 AM

Mind Cure Set To Launch Products Into Psychedelic Therapy Adaptogen Supplement Category

Mind Cure Health (CSE: MCUR) has completed the development of its first products. The company...

Tuesday, January 26, 2021, 08:43:59 AM

Mind Cure Health Focuses On Research Into Psychedelics For Traumatic Brain Injury

Mind Cure Health (CSE: MCUR) as of this morning has seen the transition of one...

Wednesday, February 17, 2021, 07:27:04 AM

Mind Cure Closes Acquisition Deal, To Be Renamed LNG Energy

Mind Cure Health Inc. (CSE: MCUR) has closed the previously announced business combination with LNG...

Wednesday, August 16, 2023, 09:38:44 AM

Mind Cure: Mental Health Focused Firm To Commence Trading Monday

Mind Cure Health (CSE: MCUR) is the latest issue to hit the Canadian Securities Exchange...

Sunday, September 20, 2020, 09:00:00 AM